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Abstract 
In this study, ultrafiltered goat milks fermented with the classical starter bacteria 
Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus salivarus subsp. 
thermophilus or with the classical starter plus the Lactobacillus plantarum C4 probiotic 
strain were analyzed using ultra-high performance liquid chromatography-quadrupole-
time-of-flight tandem mass spectrometry (UPLC-Q-TOF-MS/MS) and/or liquid 
chromatography-ion trap (LC-IT-MS/MS). Partial overlapping of the identified 
sequences with regard to fermentation culture was observed. Evaluation of the cleavage 
specificity suggested a lower proteolytic activity of the probiotic strain. Some of the 
potentially identified peptides had been previously reported as angiotensin converting 
enzyme (ACE)-inhibitory, antioxidant and antibacterial and might account for the in vitro 
activity previously reported for these fermented milks. Simulated digestion of the 
products was conducted in presence of a dialysis membrane to retrieve the bioaccessible 
peptide fraction. Some sequences with reported physiological activity resisted digestion 
but were found in the non-dialyzable fraction. However, non-previously detected 
sequences such as the antioxidant αs1-casein 144YFYPQL149, the antihypertensive αs2-
casein 90YQKFPQY96 and the antibacterial αs2-casein 165LKKISQ170 were found in the 
dialyzable fraction of both fermented milks. Moreover, in the fermented milk including 
the probiotic strain, the k-casein dipeptidyl peptidase IV inhibitor (DPP-IV) 
51INNQFLPYPY60 as well as additional ACE-inhibitory or antioxidant sequences could 
be identified. With the aim to anticipate further biological outcomes, quantitative 
structure activity relationship (QSAR) analysis was applied to the bioaccessible 
fragments and led to propose potential ACE inhibitory sequences. 
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Introduction 
Fermented milk products have a long history of being beneficial to human health. The 
physiological effects are often attributed to the action of probiotic microflora in the 
product. In milk fermentation the involved metabolites contribute to confer chemical, 
biochemical and nutritional attributes [1]. The proteolytic system of lactic-acid bacteria 
comprises extracellular cell-wall bound proteinases that initiate the degradation of milk 
proteins into oligopeptides, peptide transporters that take up the peptides into the cell, and 
various intracellular peptidases that degrade the peptides into shorter peptides and amino 
acids [2]. This can lead to the release of peptides with bioactive properties from fermented 
dairy products [3]. The proteolytic activity is influenced by the type of dairy product, the 
technology adopted and, specially, the bacterial strain [4]. In some cases, a combination 
of selected yeasts and lactic acid bacteria is used with the aim to generate peptides with 
known health benefits. Thus, a screening with lactic acid bacteria lead to select a mixed 
starter containing Streptococcus thermophilus and different Lactobacillus strains (casei, 
helveticus, plantarum) to produce goats’ milk with γ-aminobutyric acid (GABA) and 
angiotensin-I converting enzyme (ACE)-inhibitory peptides [5]. Caprine milk 
fermentation products, such as kefir, have been the source of ACE inhibitory peptides [6, 
7]. We have recently demonstrated that fermentation of ultrafiltered goat’s milk with 
lactic acid bacteria including Lactobacillus plantarum C4, a strain with demonstrated 
probiotic activity in terms of in vitro intestinal microbiota modulation [8], results in the 
development several biological activities [9]. In this regard, the proteolytic nature and 
ability to generate bioactive peptides of this strain remained to be investigated. 
There is a general agreement that caprine milk is more easily digested than bovine 
milk, a major factor affecting digestibility being the size of the lipid globules [10]. Bovine 
and caprine milk differ in protein composition and the lower content of αs1-casein in 
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goat’s milk has been associated with its lower allergenicity. Moreover, the content in this 
protein is related to milk coagulation properties, which influence protein digestibility. 
Studies on the peptides released after the simulated gastrointestinal digestion of goat milk 
proteins have shown the release of ACE [11], [12] and dipeptidyl peptidase IV (DPP-IV) 
inhibitory sequences [13] as well as antibacterial [14] and antioxidant peptides [15]. 
Interestingly, in fermented goat’s milk products, such as cheese, some peptides with 
reported physiological activities have shown resistance to in vitro gastrointestinal 
digestion, such as the antihypertensive peptide β-casein, 133LHLPLP138 [16]. 
The objective of this research was to identify the peptides produced by 
Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus with or 
without co-culture with the probiotic strain Lactobacillus plantarum C4 during the 
manufacturing of fermented goat milks. In vitro gastrointestinal digestion in combination 
with dialysis was conducted to evaluate the resistance and bioaccesibility of the released 
protein fragments. Since the assayed fermented milks had previously shown antioxidant, 
ACE-inhibitory and antimicrobial activity, comparison of the resistant peptides sequences 
with those reported in the literature and in combination of  computer-assisted prediction 
for ACE inhibition led to the identification of most bioactive peptide sequences in the 
fermented goat milks.  
 
Materials and methods 
Chemicals and samples 
Raw goat milk samples from Murciano-Granadina breed were collected from a farm in 
the region of Granada (Spain). They were skimmed by centrifugation and concentrated 
by ultrafiltration through a 50 kDa membrane (Vivaflow 2000, Sartorius Stedin Biotech, 
Madrid, Spain). Fermentation was conducted with (i) the classical starter bacteria 
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Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus salivarius subsp. 
thermophile (St) and (ii) St + the probiotic strain Lactobacillus plantarum C4 [8] (St+ 
LP). Enzymes and bile salts were purchased from Sigma Chemical Co (St Louis, MO, 
USA), porcine pepsin (P-7000), porcine pancreatin (P-1500) and porcine bile extract (B-
8631). All other reagents such as HCl, ammonia, NaHCO3, formic acid, acetonitrile, were 
purchased from Sigma Chemical. 
 
Isolation of peptide fractions 
Fermented goat milk samples were isolated based on the method developed by [17] with 
some modifications. In the first step, samples were centrifuged at 3,000 g for 30 min at 4 
ºC (Sigma 2-16PK, Sartorius, Goettingen, Germany). The precipitate was discarded and 
the supernatant was adjusted to pH 2.0 by addition of HCl. In the second step, the acidified 
supernatant was filtered through a 30 kDa cut off ultrafiltration membrane (Vivaspin20, 
Sartorius) and 100 ml of the filtrate was applied to a Dowex 50 WX2 cation exchange 
column (2.6 x 10 cm, H+-form, 200-400 mesh, Serva, Heidelberg, Germany). After 
washing with 60 ml of Milli-Q water, peptides were eluted with 200 ml of 2M aqueous 
ammonia. Ammonia was firstly evaporated in vacuo and then samples were freeze dried. 
This procedure was carried out by duplicate. 
 
In vitro gastrointestinal digestion of the fermented goat milk samples 
Fermented goat milk samples were subjected to in vitro gastrointestinal digestion in 
duplicate as described by [18]. Briefly, 20 g of each fermented milk were homogenized 
with 60 ml of Milli-Q water and subjected to gastric digestion with pepsin and duodenal 
digestion with pancreatin/bile solution. To stop intestinal digestion, samples were 
immersed in a water-bath at 100 ºC for 5 min. The digests were centrifuged at 3,500 g for 
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1 hour at 4 ºC and the supernatants, the soluble fraction, were freeze dried and kept until 
the analysis. The dialysis assay was carried out according to [18] to identify the potential 
bioaccessible peptides. It comprised a gastric step followed by an intestinal step where 
dialysis was included (dialysis bag: molecular weight 12-14 kDa; Visking 45 mm x 27 
mm, Medicell International, London, UK). Dialysis tubing, containing 25 ml of bidistilled 
deionized water and an amount of NaHCO3 equivalent to titratable acidity measured 
previously, were placed in the flasks together with 20 g aliquots of the pepsin digest and 
incubated in the shaken bath at 37 ºC for 30 min. An amount of freshly prepared 
pancreatin-bile extract mixture (0.001 g pancreatin and 0.006 g bile sals/samples) was 
added to the flask and the incubation continued up to 2 h. Dialyzable and non-dialyzable 
fractions were weighted,  freeze dried and stored until the assay. 
 
Total soluble protein content 
The total protein content of the samples was determined based on the bicinchoninic acid 
assay according to the instructions of Thermo Scientific™ Pierce™ BCA™ Protein 
Assay kit, in a 96 well plate using a FLUOStar Omega microplate reader (BMG Labtech, 
Germany). Serial dilutions with bovine serum albumin (provided with the kit) were used 
as standard. Results were expressed as mg/mL. 
 
Analysis by on-line reverse-phase high performance liquid chromatography tandem 
mass spectrometry (LC-MS/MS) 
Before injection, fermented goat milk samples after ion exchange and digested samples 
were dissolved in water with formic acid (0.1%) at 2 mg/mL protein concentration and 
centrifuged at 10,000g to precipitate all impurities. If turbidity was shown, also a filtration 
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step through 0.45 μm μm size pore filters (Millex®-GS, Merck Millipore Ltd., Cork, 
Ireland) was carried out. 
Chromatographic analysis of the samples was performed with an Acquity UPLC® 
system (Waters Technologies, Cerdanyola del Vallès, Spain) with an Acquity UPLC BEH 
130 column, a C18 column 100 mm of length, 2.1 mm of internal diameter, 1.7 μm of 
particle size and 130 Å of pore diameter (Waters Technologies, Cerdanyola del Vallès, 
Spain). The UPLC system was connected online to a quadrupole-time of flight MS/MS 
detector, equipped with an electrospray ionization source (Bruker Daltonik, Bremen, 
Germany). Solvent A was water with 0.1 % formic acid and solvent B was acetonitrile 
with 0.1% formic acid and the flow used was 0.2 mL/min. The peptide fractions were 
eluted with an isocratic gradient after 1 min of pure solvent A, up to 35 % B within 28 
min, then in 2 min 70 % of solvent B was reached and maintained during 2.5 minutes. 
The injection volume was 15 μL and the absorbance was monitored at 214 nm. The 
nebulizer pressure was set at 2 bar, the temperature of the source at 180 ºC and the 
capillary voltage at 4.5 kV Spectra were recorded over the mass/charge (m/z) range 50-
1500 and 3 spectra were averaged in the MS analyses. The signal threshold to perform 
auto MS (n) analyses was 5,000 counts and three precursor ions were isolated within a 
range of 100-1500 m/z and fragmented with a voltage ramp depending of the isolation 
mass of the precursor ion, from 20 to 70eV.  
Alternatively, the analyses were performed on an Agilent 1100 HPLC system 
(Agilent Technologies, Waldbronn, Germany) followed by on-line MS/MS analysis on 
an ion trap instrument (Esquire 3000, Bruker Daltonik GmbH, Bremen, Germany) as 
previously described [16]. Chromatographic separations were performed with a 
Mediterranea Sea18 150 mm × 2.1 mm column (Teknokroma, Barcelona, Spain). 
Samples were injected at a protein concentration of 1 mg/mL, the ﬂow rate was 0.2 
9 
 
mL/min and the injection volume was 50 µL. Peptides were eluted with a linear gradient 
from 10 % to 55 % of solvent B (acetonitrile: formic acid 0.1 %) and 45 % solvent A 
(water: formic acid 0.1%) in 95 min. Data Analysis (version 4.0; Bruker Daltoniks) was 
used to process and transform spectra. Data were processed with Data Analysis TM 
(version 4.0, Bruker Daltonik, Bremen, Germany). The m/z spectral data were processed 
with Biotools (Version 3.2, Bruker Daltonik, Bremen, Germany) where the deconvoluted 
mass spectra were matched against a homemade database with the main goat milk 
proteins (αs1-casein, αs2-casein, β-casein, κ-casein, α-lactoalbumin and β-lactoglobulin) 
sequences retrieved from the UniprotKB database (uniprot.org). Peptide sequencing was 
performed by MASCOT (matrixscience.com) with error tolerances 0.1 % for precursor 
masses and 0.5 Da for fragment masses. Only individual scores indicating identity or 
extensive homology were used. Besides,he matched MS/MS spectra were interpreted by 
using BioTools version 3.2 (Bruker). 
 
Peptide profile analysis 
Venn’s diagrams were executed with Venny 2.1 
(http://bioinfogp.cnb.csic.es/tools/venny/index.html). The Enzyme Predictor tool [19] 
was used to analyze protein cleavages in the peptides. The identified peptides were 
searched against the BIOPEP bioactive peptide database [20]. The AHT pin in silico 
platform (http://crdd.osdd.net/raghava/ahtpin/#) [21] was used in the variable length 
mode, amino acid composition model, and the SVM threshold was set to 0.9. 
 
Results and discussion 
Peptide profile analysis 
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The fermented milks were submitted to cation exchange at pH 2 followed by elution with 
ammonia in order to recover the whole peptide fraction. Fermented milk with St showed 
a higher protein concentration (0. 013 ± 0.003) than St+LP (0.009 ± 0.002). These values 
might account for the fermentation differences with more protein coagulation and less 
soluble protein/peptides in the case of St+LP, as previously observed [9]. A combination 
of two complementary LC-MS/MS settings to cover a wide range of sequence lengths 
permitted the potential identification of  a total of 232 different peptides in St and St+LP 
fermented goat milks. From these, 46 % corresponded to β-casein, 24 % to αs2-casein, 18 
% to αs1-casein and 13 % to k-casein. This distribution was compared with the content of 
the different caseins in goat’s milk. In contrast to cow’s milk, where the most abundant 
protein is αs1-casein (38 %) followed by β-casein (35 %), k- and αs2-casein (10-11 %), 
goat’s milk displays a higher proportion of β-casein (55 %) and αs2-casein (25 %) and a 
lower amount of αs1-casein (5 %) [22]. The resulting peptides are in accordance with this 
protein composition, which indicates a balanced proteolysis of the main caseins. Peptides 
from β-casein covered almost completely the sequence, but the highest number of 
peptides corresponded to the (180-207) region (Electronic supplementary material Table 
S1). Miclo et al. [23] reported this region as more accessible to the cell envelope protease 
of S. thermophilus. In contrast, the (15-40) region of β-casein was poorly represented in 
terms of potentially identified peptide sequences. This region comprises four 
phosphorylated serines and it is known that the ionization of these sequences in a complex 
mixture is difficult. However, the caseinophosphopeptides from β-casein 
15SpSpSpEESITHINK28, and 29KIEKFQSpEEQQQTED43 could be potentially identified 
in some samples. 
It has to be highlighted that peptides from αs1-casein were relatively abundant with 
regard to its low content in caprine milk (Electronic supplementary material Table S2). 
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The αs1-casein structure is composed of four parts: (1) hydrophilic region (1-12), (2) 
hydrophobic region (13-40), (3) hydrophilic region (41-99), (4) hydrophobic region (100-
199) [24]. In the present study almost all peptides were released from the hydrophobic 
regions, the most hydrolyzed region being that corresponding to the N-terminal 
hydrophobic region (22-40). Miclo et al [23] noted that the S. thermophilus cleavages 
gave rise to most peptides within the first 40 amino acid residues while the (41-99) and 
(152-159) regions appeared more resistant to hydrolysis and a low number of cleavage 
sites were observed. Accessibility to substrate was considered the determinant parameter 
in the protein susceptibility to hydrolysis rather than hydrophobicity. Besides, the missing 
peptides could derive from the phosphorylation of several residues, which impairs peptide 
ionization. Thus, the observed results show the contribution of different factors. No 
peptides from whey proteins, α-lactalbumin and β-lactoglobulin could be identified, 
which could be due to the low susceptibility of these compact proteins to the proteolytic 
action of lactic acid bacteria. 
 
Enzymatic cleavages analysis 
By the use of a sequence discrimination tool, a distinction in the generated peptides with 
regard to fermentation culture was revealed (Figure 1). More than 40 % of potentially 
identified peptides were constant in both fermented milks, which is not surprising due to 
the presence of the classical starter in both. However, the addition of the probiotic strain, 
St+LP, showed an influence on the resulting protein cleavage, with 69 exclusive 
sequences in this case, a similar number to the 62 exclusive fragments generated in milk 
fermented by the classical starter, St. In order to evaluate the hypothesis of a differential 
enzyme activity between cultures, a computer-assisted study of enzyme specificity was 
performed on the identified sequences with the EnzymePredictor program [19]. Table 1 
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shows the preferential enzyme cleavage rules determined for peptide sequences arisen by 
the action of St and St+LP. In the two best ranked enzyme specificities, no relevant 
differences could be found. However, the succeeding specificities were different between 
the fermented milks in terms of significance and a higher weight was given to the cleavage 
giving rise to C-terminal lysine or arginine in the case of St+LP. This cleavage specificity 
could be ascribed to plasmin, an endogenous enzyme in milk, responsible for the 
hydrolysis of α- and β-caseins. The stage of lactation affects plasmin activity and, with 
regard to other species, the effect in dairy goats is more pronounced since, having a 
seasonal breeding, they progress through lactation in a synchronous manner [25]. The 
higher importance of plasmin in the peptides generated by the fermented milk with St+LP 
could be attributed to a lower proteolytic power of the probiotic strain. This would explain 
this product to retain the protein cleavages present before fermentation. Therefore, 
although no particular enzyme could be distinctively predicted, the pattern indicated a 
lower proteolytic activity in  St+LP milk in comparison to the classical starter bacteria, 
St, at least at the studied fermentation time. 
 
Peptide bioactivity analysis 
These fermented milks have previously shown ACE-inhibition, antibacterial activity 
against E. coli, and antioxidant capacity using different in vitro methods [9]. Peptide 
sequences with such reported activities or very close precursors could be found, not only 
with goat’s milk origin but from bovine or ovine milk, due to the high sequence homology 
between the caseins from these dairy species. Thus, the β-casein 58LVYPFTGPIPN68, 
which has shown antihypertensive activity in spontaneously hypertensive rats [26] was 
found in samples fermented with the classical starter, St. The β-casein 
195VLGPVRGPFPI205, greatly overlaps with the antihypertensive fragment generated by 
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E. faecalis on bovine milk, 197VLGPVRGPFP206. Other potentiallyidentified peptides 
from β-casein were f(78-93), f(134-139), f(166-175), precursors of the antihypertensive 
sequences 80TPVVVPPKLPQ90, 134HLPLP138, and 169KVLPVPQ175, respectively [27], 
[26], [28]. Several peptides from the C-terminal β-casein region covered cow’s milk 
sequence 199VRGPFPIIV207, with reported antihypertensive activity [29]. Despite this, 
and due to the different penultimate residue at the C-terminal sequence, leucine in goat’s 
milk, the activity of identified peptides would probably be different to the reported by 
others. Those differences between goat and cow protein sequences were previously 
denoted as the probable reason for the difference in ACE inhibitory activity between 
200GPFPILV206 (IC50=424 μM) derived from caprine β-casein and 
191LLYQQPVLGPVRGPFPIIV209 (IC50=22 μM) released from bovine β-casein by 
hydrolysis with Lactobacillus helveticus CP790 proteinase [6].  
Regarding other biological activities, the β-casein peptide 
191YQEPVLGPVRGPFPI205, corresponds to casecidin 15, an antimicrobial sequence with 
minimal inhibition concentration against E. coli DPC6053 of 0.4 mg ml-1 [30]. On the 
other hand, the β-casein antioxidant peptide 59VYPFTGPIPN68 [31] was also potentially 
identified. Most of these physiologically active sequences were found in the fermented 
milks with both cultures (see Electronic supplementary material), which supports the 
previously antioxidant, ACE-inhibitory and antimicrobial activities observed. 
 
Peptide resistance to simulated digestion 
Simulated digestion of fermented milks was conducted with a dialysis device intended to 
recover the bioaccessible fraction of peptides resistant to the digestion conditions. The 
UV-UPLC chromatographic profile of the dialyzable and non-dialyzable fractions of a 
digested St milk sample has been evaluated (Figure 2). The chromatographic profile does 
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not greatly differ between fractions although an additional peak at 30 min can be observed 
in the non-dialyzable fraction while other peaks vary in intensity.  
In the LC-MS/MS analysis a total number of 151 different peptides could be 
potentially identified when taken together the dialyzed and non-dialyzed fractions. From 
them, 72 peptides were common to St and St+ LP milks (Figure 3). The overlapping of 
released peptides between fermentation cultures was slightly higher after digestion (47.7 
vs 43.5 %) but, still, differences in the fermented milks could be evidenced in the peptide 
profile, which supports the influence of the starter on the resulting digestome. The lower 
number of different peptides after digestion is attributed to the increase in sequence 
homology, as it has been previously observed [16]. Table 4 shows, from the common 
identified peptides, those present in the dialyzed fraction after in vitro digestion, because 
this would constitute the bioaccessible fraction. In order to know if physicochemical 
parameters of the sequences might determine their accumulation in the dialyzed fraction, 
an analysis of hydropathicity and charge of sequences was performed. The first parameter 
gives information about the structure of the peptide based on its hydrophobicity and 
hydrophilicity [32]. Notable dispersion within values was observed, with broad ranges 
observed for hydropathicity (-2.45 and 1.48) and charge (-2 to +2). Therefore, the peptides 
recovered in the dialyzed fraction could not be associated to particular features with 
regard to these physicochemical parameters.  
On the other hand, sequence descriptors permit to anticipate the biological activity 
of peptides when the rationale behind their effect is defined in relation to the amino acid 
chain. These sequences have been analyzed with a QSAR tool for ACE inhibition Kumar 
[21]. The classification model assigns the peptides to the category of potentially active 
(AHT) or inactive (non-AHT) in accordance to the specificity selected (Table 4). In this 
case the SVM score threshold was selected to provide high specificity. Positive 
15 
 
descriptions were assigned to some sequences, with relatively high scores (over 1.7) in 
the case of eight sequences derived from β- and αs1-casein. Some of these sequences had 
been reported as ACE inhibitors such as αs1-casein 151DAYPSGAW164 [33]. The 
identified β-casein f(81-89) displays an ample overlapping with β-casein ACE-inhibitor 
80TPVVVPPFLQP90 [27]. On the contrary, lower ranked sequences have also been 
described as ACE inhibitors, i. e. αs2-casein 165LKKISQ170 [34] and β-lactoglobulin 
33DAQSAPLRV41 [35]. 
The ACE-inhibition mechanism of action of peptides is not well known yet. In 
general, ACE inhibitory peptides usually contain between 2-12 amino acids [36]. Despite 
their activity has been linked to the C-terminal region composition and sometimes the N-
terminal region influences the ACE inhibitory activity of peptides with less than six amino 
acid residues, the reason for the activity of higher molecular weight peptides is still 
unknown [37]. The presence in C-terminal position of aliphatic, aromatic or branched 
chain amino acids as tryptophan, tyrosine, phenylalanine, leucine, as well as proline has 
been considered an important feature [38],[39]. Moreover, the presence of basic amino 
acids such as lysine or arginine, at the C-terminal or ultimate chain position also 
influences this activity [40]. On the other hand, some highly ranked sequences in Table 4 
have not been reported as ACE inhibitors although they fulfill these features and would 
merit further studies. This would be the case of sequences αs2-casein 
97LQYPYQGPIVL107, and β-casein 90PEIMGVPK97, and 157FPPQSVL163. 
Regarding the antioxidant activity, the presence of the hydrophobic amino acid 
residues valine or leucine at the N-terminus and proline, histidine, or tyrosine in the amino 
acid sequence are related with antioxidant peptides, and the presence and position of 
tryptophan, tyrosine and methionine are thought to be responsible for the antioxidant 
activity [41]. In addition, casein derived peptides with glutamic and aspartic acids have 
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been reported as able to inhibit lipid peroxidation and acid and basic amino acids played 
an important role in metal chelation [17]. Antibacterial activity, in turn, has been related 
with the peptide charge but the influence of additional physicochemical and structural 
properties in the mechanism of action remains to be elucidated [42]. 
Table 5 shows the peptides potentially found in the dialyzable fraction of St and 
St+LP fermented milks with reported physiological effects. Peptides with ACE 
inhibitory, antihypertensive, antioxidative, antibacterial, and DPP-IV inhibitory activities 
from the main caprine caseins and β-lactoglobulin could be found. In three cases, the 
determined sequence was comprised in a slightly longer active sequence. Some of these 
sequences are novel products from goat’s milk simulated digestion, such as k-casein 
51INNQFLPYPY60. The presence of this fragment in milk fermented with the probiotic 
culture Lactobacillus plantarum C4 after digestion deserves attention with regard to its 
potential DPP-IV inhibitory activity, related to the increase of lifetime of incretins. Some 
peptides with reported biologically activity observed before digestion were found in the 
non-dialyzable fractions, i. e. the antihypertensive β-casein 58LVYPFTGPIPN68 or the 
antimicrobial β-casein 191YQEPVLGPVRGPFPI205. The dialysis might be considered an 
approximation to the physiological conditions of the intestinal barrier. However, the 
ability of the identified peptides to interact with receptors on the intestinal epithelium or 
to cross the mucosal barrier to exert a systemic effect should be studied to consider them 
as active compounds.  
 
Conclusions 
Many peptide fragments were potentially identified in the fermented milks with both 
cultures with a distribution according to the abundance of the parent proteins in goat’s 
milk. Certain specificity could be assigned with regard to the different fermentation 
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cultures with an apparently lower proteolytic activity of the probiotic strain based on the 
specific cleavages in the resulting peptides. The ACE-inhibitory, antioxidant and 
antibacterial activities previously determined in both fermented products might be 
attributed to the presence of peptides with these physiological effects. After simulated 
digestion, some of the active sequences remained but were found in the non-dialyzable 
fraction. More importantly, digestion gave rise to new active sequences that were able to 
cross the dialysis membrane . This merits further studies on their interactions with the 
intestinal mucosa to assess their potential in exerting the physiological effects. These 
peptides have been previously described as antihypertensive, antibacterial, antioxidative 
or DPP-IV inhibitors. Moreover, the application of QSAR analysis to the dialyzed peptide 
fragments after digestion allowed to designate new sequences that are candidates to be 
bioaccessible ACE inhibitors. 
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Figure captions 
Figure 1. Venn diagrams of the peptide sequences potentially identified in the goat milk 
fermented with the classical starter, St, and the classical starter plus Lactobacillus plantarum C4, 
St+LP 
 
Figure 2. UV-chromatographic profile of a) dialyzable fraction b) non-dialyzable fraction of 
goat’s milk fermented with the classical starter, St. 
 
Figure 3. Venn diagrams of the peptide sequences potentially identified in the goat milk 
fermented with the classical starter, St, and the classical starter plus Lactobacillus plantarum C4, 
St+LP after in vitro gastrointestinal digestion. 
  
19 
 
Table1 Cleavage patterns computationally determined of the fermented milk peptide profile. 
Three amino acids upstream (P1, P2, and P3) and two downstream (P1’ and P2’) of the N and C 
-terminal cleavage sites are used. 
Ranking1 
Cleavage specificity 
P3 P2 P1 P1’ P2’ 
1 Not H, K, 
R 
Not P Not R F, L, W, 
Y 
Not P 
2   F, L or Y Not  P  
3   K or R   
1Based on odds ratio by EnzymePredictor.  
 
H: Histidine, K: Lysine, R: Arginine, P: Proline, F: Phenylalanine, L: Leucine, W: 
Tryptophan, Y: Tyrosine. 
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Table 2. Peptides identified in fermented milks after in vitro digestion plus dialysis. Prediction 
for antihypertensive using the AHTpin platform. Support vector machine (SVM) score 
(threshold=0.9). 
Protein Fragment Peptide sequence Hydropathicity Charge 
SVM 
Score 
Prediction 
αs1-casein 24 - 31 VVAPFPEV 1.31 -1 1.74 AHT 
24 - 32 VVAPFPEVF 1.48 -1 1.80 AHT 
32 - 39 FRKENINE -1.89  0 0.01 Non-AHT 
56 - 41 DAKQMK -1.85  1 0.09 Non-AHT 
77 - 82 EQKYIQ -1.87  0 -0.65 Non-AHT 
110 - 114 EIVPK -0.06  0 0.87 Non-AHT 
142 - 149 LAYFYPQL 0.56  0 1.68 AHT 
143 - 149 AYFYPQL 0.10  0 1.63 AHT 
144 - 149 YFYPQL -0.18  0 1.11 AHT 
148 - 164 YQLDAYPSGAW -0.54 -1 1.92 AHT 
150 - 154 FRQFY -0.74  1 0.29 Non-AHT 
151 - 164 DAYPSGAW -0.61 -1 1.70 AHT 
165 - 172 YYLPLGTQ -0.15  0 -0.05 Non-AHT 
173 - 179 YTDAPSF -0.47 -1 1.00 AHT 
αs2-casein 20 - 25 IYKQEK -1.93  1 -1.06 Non-AHT 
26 - 32 NMAIHPR -0.66  1 1.13 AHT 
90 - 96 YQKFPQY -1.76  1 1.00 AHT 
97 - 107 LQYPYQGPIVL 0.28  0 1.35 AHT 
165 - 170 LKKISQ -0.63  2 -0.14 Non-AHT 
165 - 171 LKKISQY -0.73  2 -0.47 Non-AHT 
181 - 189 LKTVDQHQK -1.58  1 -0.79 Non-AHT 
183 - 189 TVDQHQK -2.01  0 -0.49 Non-AHT 
184 - 189 VDQHQK -2.23  0 0.65 Non-AHT 
190 - 198 AMKPWTQPK -1.38  2 0.39 Non-AHT 
β-casein 1 - 6 REQEEL -2.45 -2 1.00 AHT 
81 - 89 PVVVPPFLQ 1.21  0 1.92 AHT 
90 - 97 PEIMGVPK -0.05  0 1.85 AHT 
98 - 107 VKETMVPKHK -1.04  2 0.89 Non-AHT 
100 - 105 ETMVPK -0.6  0 0.11 Non-AHT 
157 - 163 FPPQSVL 0.47  0 2.07 AHT 
182 - 187 DMPIQA -0.07 -1 0.35 Non-AHT 
188 - 205 LLYQEPVLGPVRGPFPIL 0.61  0 1.38 AHT 
189 - 205 LYQEPVLGPVRGPFPIL 0.42  0 1.63 AHT 
190 - 196 LYQEPVL 0.27 -1 1.04 AHT 
190 - 205 YQEPVLGPVRGPFPIL 0.21  0 1.91 AHT 
k-casein 18 - 24 FDDKIAK -0.81  0 1.31 AHT 
42 - 48 YYQQRPV -1.64  1 1.15 AHT 
69 - 75 SPAQTLQ -0.64  0 -0.16 Non-AHT 
96 - 104 ARHPHPHLS -1.39  1 0.75 Non-AHT 
β-lg 32 - 41 DAQSAPLRV -0.26  0 0.34 Non-AHT 
51 - 57 EGNLEIL 0.17 -2 -0.18 Non-AHT 
β–lg: β-lactoglobulin 
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Table 3. Peptides with reported biological activity in the dialyzable fraction of fermented goat milks 
with classical starter (St), classical starter plus Lactobacillus plantarum C4 (St+LP) or both. 
Protein Fragment Sequence Activity Reference 
St and St+LP     
αs1-casein 151-164 DAYPSGAW ACE Inhibitor [33] 
αs1-casein 144-149 YFYPQL Antioxidative [43] 
αs2-casein 90-96 YQKFPQY Antihipertensive [38] 
αs2-casein 165-170 LKKISQ 
Antibacterial 
ACE Inhibitor 
[44] 
[45] 
β-casein 81-89 PVVVPPFLQ 
ACE Inhibitor 
(TPVVVPPFLQP
) 
[27] 
k -casein 96-104 ARHPHPHLS Antioxidative [46]  
β-lg 33-41 DAQSAPLRV 
ACE Inhibitor 
(DAQSAPLRVY) 
[35] 
St     
k-casein 96-105 ARHPHPHLSF 
Antioxidative 
(ARHPHPHLSF
M) 
[46]  
St + LP     
β-casein 108-113 EMPFPK ACE Inhibitor [33] 
k-casein 25-30 YIPIQY 
ACE Inhibitor 
Antioxidative 
[47] 
[48] 
k-casein 51-60 INNQFLPYPY DPP-IV inhibitor [12] 
β–lg: β-lactoglobulin 
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